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PPARαToll-like receptor (TLR) signaling plays a fundamental role in the induction and progression of autoimmune
disease. In the present study, we showed that lipopolysaccharide (LPS), a TLR4 ligand, functions as an antagonist
of peroxisome proliferator-activated receptor alpha (PPARα), a nuclear transcription factor. Using endotoxin in-
duced uveitis (EIU) as a model, we found that TLR was negatively regulated by PPARα. Our data revealed that
treatment with the PPARα agonist fenoﬁbrate dramatically prevented LPS-induced uveitis and inhibited TLR/
Nuclear factor-kappaB (NF-κB) signaling during inﬂammation. Evaluation of the severity of anterior uveitis fur-
ther showed that PPARα agonist treatment signiﬁcantly decreased inﬂammatory cell inﬁltration, total protein
concentration, vessel density, inﬂammatory cytokine production, and clinical scores in the anterior section of
the eye during EIU. Moreover, fenoﬁbrate administration recovered retinal function and decreased the produc-
tion of inﬂammatory cytokines, retinal vascular leukostasis, and inﬂammatory cell inﬁltration into the posterior
section of the eyes during EIU. In vitro studies further showed that down-regulation or deletion of PPARα led to
increased TLR4 levels and the activation of NF-κB signaling in RPE cells and also blocked the anti-inﬂammatory
effects of fenoﬁbrate. Furthermore, activation or up-regulation of PPARα decreased TLR4 levels and inhibited
the NF-κB signaling pathway induced by LPS in RPE cells. In TLR4-expressing reporter cells, activation or up-
regulation of PPARα partially inhibited the activation of NF-κB and also decreased TLR4 transcriptional activity.
In conclusion, the activation of PPARα represents a novel therapeutic strategy for human uveitis, as PPARα neg-
atively regulates TLR4 activity and therefore exerts anti-inﬂammatory actions.
Published by Elsevier B.V.1. Introduction
The Toll-like receptors (TLRs) constitute a family of recently discov-
ered innate immune recognition receptors, which play fundamental
roles in the induction of innate immunity, inﬂammation, cell survival,
and proliferation. The activation of TLR signaling is mediated through
the binding of various ligands, including lipids, lipoproteins, proteins,
and nucleic acids derived from bacteria, viruses, and fungi. Thus far,
10 TLRs have been identiﬁed in humans and 12 functional TLRs in
mice, and TLR1 to TLR9 are highly conserved in both humans and
mice [1,2]. The best-studied member of the TLRs is TLR4, which isU, experimental autoimmune
polysaccharide;MyD88,myeloid
PARs, peroxisome proliferator-
l/IL-1R; TNF-α, tumor necrosis
ch Foundation, Oklahoma City,
d., BSEB 313, Oklahoma City, OK
n@ouhsc.edu (Y. Chen).primarily associated with the accessory protein MD-2 and the co-
receptor CD14 to recognize lipopolysaccharide (LPS), a glycolipid com-
ponent of the outer membrane of Gram-negative bacteria. LPS recogni-
tion then activates the Toll/IL-1R (TIR) domain-containing adaptor
molecule MyD88 (myeloid differentiation factor 88)-dependent path-
way [3,4]. TLR4 is expressed on the cell surface and cycles between
the Golgi and the plasma membrane in both immune cells, such as
monocytes/macrophages, and nonprofessional immune cells, such as
epithelial cells [4–6]. The expression of TLR4 plays a pivotal role in
host defense, and inappropriate TLR4 activation can result in the accel-
eration of inﬂammatory and autoimmune diseases.
One example of aberrant TLR4 activation is LPS-induced endotoxin
induced uveitis (EIU), a widely used experimental induction of uveitis
for studying the mechanisms of innate inﬂammation and for validating
potential therapeutic modalities for human uveitis, which constitutes
an ocular emergency and is one of the leading causes of legal blindness
in the US [7–9]. Experimental induction of EIU is achieved through sub-
cutaneous injection with one dose of LPS, which specially targets the
uvea-resident tissues consisting of pigmented epithelial cells and the
vascular cells of the eye. Injection of LPS results in TLR4 signaling in
cooperation with MyD88 to activate NF-κB, culminating in potent
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mRNA could contribute to endotoxin tolerance, whereas the lack of
TLR4 in rodents has resulted in resistance to EIU [4,11,12].
Peroxisome proliferator-activated receptor alpha (PPARα) is a tran-
scription factor that is highly expressed in vascular cells and pigment
cells. In addition to controlling the expression of genes involved in lipid
metabolism, recent studies have found that activation of PPARα amelio-
rates inﬂammation by inhibiting NF-κB activity [13,14], suppressing pro-
inﬂammatory cytokine production [15,16], and modulating endothelial
neutrophil production [17]. Despite these ﬁndings, the precise mecha-
nism responsible for these effects of PPARα and its relationship with
TLR4 remains obscure.
Using themodel of EIU, we evaluated the therapeutic importance of
PPARα activation for LPS-induced uveitis, andwe found that PPARα acts
as a TLR4 repressor by inhibiting TLR4 transcription and that, contrary to
its role as a TLR4 activator, LPS acts as a PPARα antagonist. Thus, the
manner in which LPS induces TLR4 transcription is through the inhibi-
tion of PPARα, and our study therefore provided a novel mechanistic
insight into TLR signaling in auto-inﬂammatory diseases.
2. Materials and methods
2.1. Animals
All animal experiments were conducted in strict agreement with
the Association for Research in Vision and Ophthalmology (ARVO)
Statement for the use of Animals in Ophthalmic and Vision Research.
Adult male Lewis rats (age range, 8–10 weeks; weight range, 150–
200 g) were purchased from Charles River (Wilmington, MA) and
kept in 12 h light/12 h dark cycle in the animal facility at the University
of Oklahoma Health Science Center (Oklahoma City, OK).
2.2. Endotoxin-induced uveitis
Lewis rats (Charles River Laboratories, Wilmington, MA), 10 week
old, were randomly distributed into three groups (12 rats each group)
and were subcutaneously injected with 200 μg LPS (Sigma-Aldrich,
St. Louis, MO) into their hindback. All the rats were euthanized 24 h
after LPS injection. For fenoﬁbrate treatment group, rats were fed a
chow containingwith fenoﬁbrate (120 mg/kg/d) for 7 days and followed
with the EIU induction.
2.3. Clinical evaluation of EIU
Slit lamp examination was conducted 24 h after the LPS injection
before the euthanization. Pictures of the anterior part reﬂecting the
visualization were taken by the handle hold retina camera (Kowa,
Japan). Clinical scoring of the EIU was performed as follows [18]: the
severity of the EIU was graded from 0 to 4 using the scale: 0 = no
inﬂammatory reaction; 1 = discrete inﬂammation of the iris and
conjunctival vessels; 2 = dilation of the iris and conjunctival vessels
with moderate fare in the anterior chamber; 3 = hyperemia in iris as-
sociated with Tyndall effect in the anterior chamber; 4 = same clinical
signs as 3 plus the presence of ﬁbrin or syncehiae.
2.4. Induction of experimental autoimmune uveitis (EAU)
Male Lewis rats at age of 10 weekswere immunized by subcutaneous
(hindback) injection with a single dose of 50 μg recombinant human
retinal soluble antigen (SAg) peptide S35 (341–360) (AnaSpec Inc., San
Jose, CA), emulsiﬁed with complete Freund's adjuvant (1:1 w/v)
(Sigma-Aldrich, St. Louis, MO) and supplemented with pertussis H37Ra
at 2.5 mg/ml (Difco, Detroit, MI). Controls were injected with the same
amount of CFA, emulsiﬁed with saline (200 μl per rat). The severity of
thediseasewas inspected by slip lamp starting from the7thday following
immunization. Twenty one days after immunization, the rats wereeuthanized and the eyes were collected for experiments. For fenoﬁbrate
treatment group, rats were pre-fed a chow containing with fenoﬁbrate
(120 mg/kg/d) for 1 day and then 21 days right after the induction.
2.5. Electroretinogram (ERG) recording
ERG was recorded with a gold electrode placed on the cornea, a
reference electrode in the mouth, and a ground electrode on the tail.
Dark adaptation was for 12 h and the light adaptation was for 5 min.
The ﬂash intensities for scotopic and photopic ERG were 1000 and
2000 cd·s/m2, respectively. The ERG waveforms of both eyes in the
same animal were simultaneously recorded.
2.6. Histopathologic evaluation of EIU
After the euthanization, the eyes were nucleated immediately and
stored in 4% PFA solution at 4 °C and embedded in parafﬁn. The 10-
μmsagittal sectionswere cut through the nerve and stainedwith hema-
toxylin and eosin. For histopathologic evaluation, the anterior and
posterior chambers were examined with the light microscopy.
2.7. Cell inﬁltration and protein concentration in aqueous humor
Aqueous humor was collected by anterior chamber puncture with
an insulin syringe immediately after the euthanization of the rats. For
the cell counting, 1 μl of aqueous humor was diluted in 9 μl PBS and
then suspended with 10 μl Trypan blue solution, and the cells were
counted with a hemocytometer under the light microscopy. The
number of cells per ﬁeld (an equivalent of 0.1 μl) was obtained by aver-
aging the results of four ﬁelds from each sample. The total protein con-
centration in the aqueous humor was measured by Coomassie Blue
assay. The aqueous humor samples were centrifuged at 2500 rpm for
5 min at 4 °C to obtain the supernatant. All the aqueous humor samples
were stored in the ice until tested, and cell counts and total protein
concentration were measured on the day of sample collection.
2.8. Evaluation of retinal vascular adherent leukocytes
Leukocyte adhesion to the retinal vessels was evaluated 24 h after
EIU induction. Brieﬂy, rats were anesthetized and perfused through
the left ventricle with PBS to remove circulating leukocytes in blood
vessels. The adherent leukocytes in the vasculaturewere stained by per-
fusion with FITC-conjugated concanavalin-A (Con-A; 40 μg/ml, Vector
Laboratories, Burlingame, CA). The eyes were removed and ﬁxed in 4%
paraformaldehyde. The retinas were dissected and ﬂat-mounted.
Adherent leukocytes in the retinal vasculature were counted under a
ﬂuorescence microscope.
2.9. Cell culture and primary cell culture
ARPE 19 cells were cultured in a DMEM medium containing 10%
Fetal Bovine Serum and 1% Ampicillin. At conﬂuence of 95%, cells were
exposed to 1 μg/ml LPS in the presence or absence of 50 μM fenoﬁbrate,
10 μM GW6471 (Sigma, St. Louis, MO) or 50 μM WY 14643 (Sigma,
St. Louis, MO) for 24 h. For primary cell culture, tissues isolated
from C57/BL6 and Pparα−/− mice (3–4 week old) were minced,
digested, plated and cultured in DMEMmedium containing 5% FBS, 1%
antibiotics, 1% no essential amino acid, 1% insulin transferrin selenium
and 20 mM HEPES.
2.10. Immunohistochemisty
Immunohistochemistry was followed a procedure as described
previously [19]. Antibodies: mouse anti-NF-κB (1:100, Abcam,
Cambridge, MA), rabbit anti-TLR4 antibody (1:100, Abcam, Cambridge,
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goat anti-rabbit IgG (H + L) (1:100, Invitrogen, Eugene, OR).
2.11. Western blotting analysis
Western blotting analysis was followed a procedure as described
previously [19]. The antibodies are: rabbit anti-phosphorylated-NF-κB
(1:1000, Santa-Cruz Biotechnology), mouse anti-TLR4 (1:1000,
Abcam, Cambridge, MA), rabbit anti-ICAM-1 (1:500, Cell Application,
San Diego, CA), rabbit anti-TNF-α (1:500, Cell Application, San Diego,
CA), rabbit anti-VEGF (1:1000; Santa-Cruz Biotechnology, Santa-Cruz,
CA), rabbit anti-MCP-1 (1:500; Abcam, Cambridge, MA), rabbit anti-
TLR4 antibody (1:1000, Abcam, Cambridge, MA), and mouse anti-β-
actin (1:5000; Sigma-Aldrich, St. Louis, MO).
2.12. Quantitative real-time reverse transcription (RT)-PCR
Quantitative real-time PCR was followed a procedure as described
previously [19]. TLR-4 primers: 5′-AGAACTGCAGGTGCTGGATT-3′ and
3′-AAACTCTGGATGGGGTTTCC-5′.
2.13. Construction of the TLR4 promoter
A segment containing 500 bp of upstream and 100 bp of down-
stream sequence relative to the predicted transcription start site (TSS)
of the human TLR4 gene was ampliﬁed by a PCR from human genomic
DNA. The ampliﬁed promoter fragments were digested with the appro-
priate restriction enzymes (New England Biolabs, Ipswich, MA) and
cloned into the reporter gene expression vector pGLuc-04 (Promega,
Madison, WI), which contains a Fireﬂy luciferase reporter gene down-
stream from the multiple cloning sites.
2.14. TLR4 promoter activity assay
ARPE19 cells (1 × 104 cells/well of 24-well dish) were co-transfected
with 0.1 μg p-human TLR4 promoter-Luc and 20 ng Renilla luciferase ex-
pression vector pGL4.75 (Promega,Madison,WI) as an internal control by
lipofection. Twenty-four hours after achieved optimal efﬁciency, cells
were cultured in a medium containing with or without WY14643
(50 μM) and GW6471(10 μM) for 24 h and then exposed to LPS (1 μg/
ml) for 1 h. Luciferase activities of each group cells were measured by
using the Dual-Luciferase Reporter Assay System Kit (Promega, Madison,
WI).
2.15. Monitoring NF-κB activation
At a conﬂuence of 90%, ARPE19 cells were transfected with a vector
carrying an inducible secreted embryonic alkalinephosphatase (SEAP) re-
porter gene, which was under the control of an ELAM-1 (E-selectin) pro-
moter fused to ﬁve NF-κB and AP-1-binding sites (Invivogen, San Diego,
CA). Forty-eight hours after transfection, the cells were exposed to a cul-
ture medium containing with or without various ranges of fenoﬁbrate,
WY14643 or GW6471 overnight and then exposed to 0.1 ng/ml LPS-EB
Ultrapure (Invivogen, San Diego, CA) for 1 h. Levels of SEAP (indicating
the NF-κB and AP-1 activities) were detected and quantiﬁed by Quanti-
Blue following manufacturer's protocols (Invivogen, San Diego, CA).
HEK293 reporter cells with stably expressed human TLR4, MD-2
and CD14 co-receptor genes, and an inducible SEAP reporter gene
controlling an IL-12 p40 minimal promoter fused to ﬁve NF-κB and AP-
1-binding sites were stimulated with a range of fenoﬁbrate (0–100 μM)
for 24 h and 0.1 ng/ml LPS-EB for another hour. Levels of SEAP were de-
tected and quantiﬁed by Quanti-Blue following manufacturer's protocols
(Invivogen, San Diego, CA).
C3H/TLR4mut reporter cells were generated from TLR4-deﬁcient
murine embryonic ﬁbroblasts and stably express an NF-κB inducible
SEAP reporter gene (Invivogen, San Diego, CA) and were served ascontrol in this study. The mutant reporter cells were stimulated with
0.1 ng/ml TLR2 and TLR3 agonists and LPS-EB in the presence of a
range of fenoﬁbrate orWY14643 at a concentration of 50 μM. Levels of
SEAP was detected and quantiﬁed by Quanti-Blue following a manufac-
ture protocols (Invivogen, San Diego, CA).
2.16. PPARα activity assay
The responsive reporter cells which expressed the encoding human
NR1C1 gene (PPARα) and luciferase were dispensed into 96 wells
(5 × 103 cells/well) of assay plate and exposed to a medium containing
various ranges of GW590735 (0–100 nM) or WY14643 (0–100 μM) to
reach an effective concentration value. At a value of EC50, the reporter
cells were exposed to LPS at different doses (0–4 ng/ml) overnight fol-
lowing manufacturer's protocol (Indigo Bioscience, PA). The luciferase
activities were quantiﬁed by the intensity of light emission from each
sample using a luminometer.
2.17. Statistical analysis
Data were presented as mean ± SD. Statistical analyses were per-
formed using the Mann–Whitney U test or ANOVA test. A p-value
b 0.05 was considered as statistically signiﬁcant.
3. Results
3.1. PPARα agonist inhibited ocular inﬂammation in EIU and EAU
rat models
Firstly, we examinedwhether fenoﬁbratewas capable of ameliorating
the ocular inﬂammation and rescuing retinal function during EIU. Adult
Lewis rats were pre-fed with fenoﬁbrate for 1 week and then injected
with LPS to induce EIU. Twenty-four hours following the induction, the
severity of EIUwas evaluated. LPS injection induced an average clinical in-
ﬂammation score of ~2.8 (p b 0.001 vs. control). Treatment with
fenoﬁbrate signiﬁcantly reduced the clinical score to 1.2 (p b 0.01,
Fig. 1A & B). Quantitative analysis for the inﬂammatory cellular inﬁltra-
tion and protein leakage in the Aqueous Humor (AqH) showed 118 ±
22.93 × 105 cells/ml (p b 0.001 vs. controls 0) (Fig. 1C) and 6.3397 ±
0.07 mg/ml leakage protein (p b 0.01 vs. controls 2.86428 ±
0.753 mg/ml) (Fig. 1D) in EIU rats, which was signiﬁcantly reduced
by oral fenoﬁbrate to 10.07 ± 2.8 × 105 cells/ml (p b 0.0001 vs. EIU)
(Fig. 1C) and 1.944 ± 0.923 mg/ml (p b 0.001 vs. EIU) (Fig. 1D),
respectively.
We investigated the effect of fenoﬁbrate on monocyte chemo-
attractant protein (MCP)-1, a chemokine which plays crucial role in
the induction of EIU, and VEGF, a major angiogenic factor for vasculari-
zation and a key mediator for increased vessel permeability to cause
protein leakage, in anterior segment of the eye. LPS induction dramati-
cally increased in AqH MCP-1 and VEGF and the increases were
suppressed by fenoﬁbrate to a level comparable to the controls
(Fig. 1E and 1F). Histopathologic analysis of the cell inﬁltration showed
high cell inﬁltration in anterior and posterior segments of the eye from
rats during EIU, and treatmentwith fenoﬁbrate reduced the cell inﬁltra-
tions (Fig. 1G). Immunohistochemistry study of NF-κB demonstrated an
intensive signal in the anterior eye from EIU rats and aweak signal from
controls and EIU rats treated with fenoﬁbrate (Fig. 1H).
We examined the effect of fenoﬁbrate on leukostasis, an early pro-
cess of inﬂammation whereby inﬂammatory cytokines transmigrate
into tissues, during EIU. As shown in Fig. 2A and B, LPS injection resulted
in leukocyte attachment to the endothelial cells of retina, whichwas po-
tently suppressed by pre-treatment with fenoﬁbrate. During EIU, levels
of VEGF and MCP-1 were remarkably increased in the eyecups and
treatment with fenoﬁbrate signiﬁcantly prevented the release of these
inﬂammatory markers (Fig. 2C and D). The effects of fenoﬁbrate on
retinal functions were examined by ERG. Compared with the controls,
Fig. 1. Therapeutic potential of PPARα agonist on anterior eye during EIU. Adult Lewis rats were pre-treated with fenoﬁbrate (120 mg/kg/d) for 7 days and then induced EIU with LPS.
Twenty-four hours following induction, the rats were subjected for studies. A: Representative ocular photography was taken at 24 h following induction. B: Clinical inﬂammatory scores
of EIU in Lewis rats in the absence or presence of fenoﬁbrate were determined at 24 h after LPS injection. C: Cell inﬁltrations in the anterior chamber (AqH) of the EIU rats with or without
fenoﬁrate pre-treatment. D: Total protein in AqHwasmeasured and compared (B–D, Mann–Whitney U test was used for analysis. Normal: n=6; EIU: n=7; EIU-fenoﬁbrate: n=7,
**p b 0.05, ***p b 0.001). E & F:Western blot analysis ofMCP-1 andVEGF inAqH fromrats of control, EIU and EIUpretreatedwith fenoﬁbrate. Each lanepresents one individual animal. G:
Representative ocular sectionswere fromnormal rats, EIU rats, and EIU rats pre-treatedwith fenoﬁbrate. Scale bar: 50 μM.H: Representative immunocytochemical staining of NF-κB in the
anterior segment of the eyes from normal rats, EIU rats, and EIU rats pre-treated with fenoﬁbrate. Scale bar: 20 μM.
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a level approximately 60% in A wave and 40% in B wave of that in age-
matched control rats (p b 0.05 vs. normal) (Fig. 2E), suggesting compro-
mised rod functions. Feedingwith fenoﬁbrate returned the decreased A
wave and B wave to the approximate levels of 70% and 80% in control
rats, respectively (p b 0.05 vs. EIU rats without fenoﬁbrate treatment)
(Fig. 2E), indicating a rescuing effect of fenoﬁbrate on rod functions. Inall EIU groups, both A wave and B wave amplitudes in photopic ERG
were not signiﬁcantly changed compared with the control group.
The anti-inﬂammation effects of fenoﬁbrate on EAU were examined
in rats immunizedwith human SAg peptide aswell. Ocular histopathol-
ogy examination in normal rats, EAU rats, and EAU rats treated with
fenoﬁbrate on day 21 revealed severe photoreceptor destruction and
retinal disorganization in EAU rat, which was completely prevented by
Fig. 2. Therapeutic potential of PPARα agonist on posterior eye during EIU. A: Retinal vascular endothelial cells and adherent leukocytes were stained with FITC conjugated Con-A (green)
in normal rats, EIU rats, and EIU rats pre-treatedwith fenoﬁbrate after the circulating leukocytes were removed by perfusion. The retinaewere ﬂat-mounted, and the adherent leukocytes
were visualized and calculated. Scale bar: 20 μM. B:Multiple leukocytes adherent to endotheliumof retinal vasculaturewere observed in the retina fromEIU rats but not in the normal rats.
Feeding with fenoﬁbrate reduced the leukocytes attachments (mean ± SD, n= 4, **p b 0.01). C–D: The levels of VEGF and MCP-1 in the eyecups from normal rats, EIU rats, and EIU rats
pre-treatedwith fenoﬁbrate were determined byWestern blot analysis and normalized by β-actin levels. E: Statistic scotopic and photopic ERG showed the changes of B wave in scotopic
ERG in normal rats, EIU rats, and EIU rats pre-treated with fenoﬁbrate (mean ± SD, n= 3, **p b 0.01).
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retinal inﬂammatory cytokines indicated high levels of TLR4, iris and
vitreous VEGF, MCP-1, TNF-α, and NF-κB in EAU rats but not in normal
rats and EAU rats treatedwith fenoﬁbrate (Supplemental Fig. 2B). These
results support the ﬁnding that fenoﬁbrate has a therapeutic potential
for ocular inﬂammation.
3.2. The PPARα agonist fenoﬁbrate attenuated LPS-induced cytokine
production and inhibited NF-κB signaling in RPE cells
RPE cells express a variety of cytokines and adhesion molecules,
which contribute to the inﬂammatory response of the retina andmaintain the eye as an immune-privileged site. Given that PPARα ago-
nists are capable of preventing the ocular inﬂammation induced by
LPS in vivo, we examined whether the PPARα agonist fenoﬁbrate
could inhibit the production of inﬂammatory cytokines involved in
downstream LPS/TLR4 signaling in RPE cells. ARPE19 cellswere exposed
to LPS and were treated with fenoﬁbrate or with vehicle as a control.
The cellular levels of tumor necrosis factor alpha (TNF-α), which is
induced and released upon LPS binding to TLR4, and ICAM-1, which
can be stimulated by both LPS and TNF-α, were assessed usingWestern
blotting. As shown in Fig. 3, exposure to LPS stimulated signiﬁcant
increases in TNF-α (p b 0.01 vs. vehicle, Fig. 3A and C) and ICAM-1
(p b 0.01 vs. vehicle, Fig. 3B and D), which were signiﬁcantly reduced
Fig. 3. PPARα agonists attenuated LPS-induced cytokine production and inhibited NF-κB activation in RPE cells. Conﬂuent RPE cells were cultured in the absence or presence of 50 μM
fenoﬁbrate for 24 h and exposed to 1 μg/ml LPS for 1 h. A–F: Representative blots analysis of cellular TNF-α, ICAM-1, and phosphorylated NF-κB levels in the whole cell lysis from RPE
cells. Semi-quantiﬁed by densitometry and normalized by β-actin (mean ± SD, n= 5, **p b 0.01). G: Representative immunocytochemical analysis of the effect of fenoﬁbrate on
NF-κB nuclear translocation in RPE cells exposed to LPS. Scale bar: 20 μm in upper panel and 50 μm in lower panel.
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LPS, Fig. 3A–D).
To assess the role of fenoﬁbrate in LPS/TLR4 signalingmore accurately,
we examined NF-κB nuclear translocation and phosphorylation, which
both serve as indicators of downstream signaling following TLR4 activa-
tion. Exposure of RPE cells to LPS elevated NF-κB phosphorylation and
induced NF-κB nuclear translocation, and these effects were fully
reversed by the co-application of fenoﬁbrate at a concentration of
50 μM(Fig. 3E–H, arrows in Fig. 3H showingNF-κBnuclear translocation).3.3. PPARα agonist treatment suppressed TLR4 expression and inhibited
TLR4 signaling
To further conﬁrm the speciﬁcity of fenoﬁbrate on TLR4/NF-κB sig-
naling, RPE cells were transiently transfected with a vector expressing
MD-2 and the secreted embryonic alkaline phosphatase (SEAP) reporter
gene under the control of NF-κB. These cells then were stimulated with
LPS in the presence of fenoﬁbrate or vehicle, and activation of TLR4 sig-
naling was measured according to SEAP activity. LPS exposure induced
Fig. 4. PPARα agonist suppressed TLR4 expression and inhibited TLR4 signaling. A: ARPE 19 cells at conﬂuence of 90% were transfected with 1 μg plasmid DNA containing a SEAP reporter gene under controlling by NF-κB/AP-1. The same amount
control vector served as negative control. Forty-eight hours after reaching the acquiescence in the freshly prepared medium, the cells were exposed to 1 μg/ml LPS in the absence or presence of 50 μM fenoﬁbrate for 24 h. The NF-κB transcriptional
activitywasmeasured by SEAP activity. B: The C3H/TLR4mutant reporter cells with stably expressedNF-κBwere exposed to 1 μg/ml LPS or 100 μg/ml of Pam3CSK4 for 24 h, the NF-κB transcriptional activity wasmeasured by SEAP activity. C & D: At
conﬂuence, the C3H/TLR4mut reporter cells were exposed with or without 100 μg/ml of Pam3CSK4 or 1 μg/ml of LPS in the presence of 50 μM fenoﬁbrate for 24 h. The NF-κB transcriptional activity was determined by SEAP activity. E: The reporter
cells with stably expressed TLR4/MD-2/NF-κBwere cultured in the presence of fenoﬁbrate at doses of 0, 25, 50 and 100 μM for 24 h and then exposed to 1 μg/ml LPS for 1 h. The NF-κB transcriptional activity indicating the SEAP activity wasmeasured
(mean±SD, n=5, ###p b 0.01 vs. controlwithout LPS; ***p b 0.001 vs. LPS). F &G: RepresentativeWestern blot analysis of TLR4 levels in the iris of normal rats, EIU rats, andEIU rats pre-treatedwith fenoﬁbrate. The TLR4 levelswere semi-quantiﬁed
by densitometry and normalized by β-actin levels (mean± SD, n=3, ***p b 0.001). H & I:Western blot analysis of TLR4 levels in control ARPE19 cells, and ARPE19 cells exposed to LPS in the presence with/without fenoﬁbrate. The TLR4 levels were
semi-quantiﬁed by densitometry and normalized by β-actin levels (mean ± SD, n= 3, ***p b 0.001). J: Representative immunocytochemical staining of TLR4 and NF-κB in RPE cells. Scale bar: 20 μm in large images and 50 μm in small images.
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which was markedly reduced in response to fenoﬁbrate treatment
(Fig. 4A). In 293T reporter cells, which stably co-express the human
TLR4/MD-2/CD14 gene and NF-κB/AP1-inducible SEAP reporter gene,
LPS stimulation induced a similar increase in NF-κB signaling, whereas
this increasewas partially reduced following treatmentwith fenoﬁbrate
(Fig. 4B–D). However, increased fenoﬁbrate concentrations did not
result in dose-dependent reductions in NF-κB signaling in stable report-
er cells (Fig. 4E), indicating that fenoﬁbrate likely inhibits TLR4/NF-κB
signaling via effects on upstream pathway components. To address
this possibility, we examined TLR4 levels in the uveas of EIU rats and
in ARPE19 cells by Western blot analysis. In EIU rats, LPS challenge
resulted in a remarkable increase in the levels of TLR4 in the iris, where-
as greater than 60% of this increase was reduced by treatment with
fenoﬁbrate (Fig. 4F and G). Similarly, exposure to LPS induced a two-
fold increase in TLR4 expression compared to the control, whereas the
presence of fenoﬁbrate returned TLR4 expression to the basal level in
ARPE19 cells (Fig. 4H and I).
Immunocytochemistry revealed that TLR4 signalingwas remarkably
increased and shifted from the cell surface to the cytoplasm following
LPS stimulation, which were completely reversed in response to
fenoﬁbrate treatment. Consistently, exposure to LPS induced NF-κB
nuclear translocation which was inhibited by fenoﬁbrate (Fig. 4J).
These results suggested that fenoﬁbrate inhibited TLR4/NF-κB signaling
likely through down-regulating TLR4.3.4. PPARα agonist treatment ameliorated inﬂammation and inhibited
TLR4/NF-κB signaling in a PPARα-dependent manner
PPARα is abundant in the liver, and in PPARα knockout mice, the
hepatic PPARα was shown with a complete cleanup (Supplemental
Fig. 3). To determine whether the presence of PPARα is essential for
inhibition of TLR4 and inﬂammatory cytokine production, we established
a parallel study in primary liver cells cultured from wild-type (wt) or
Pparα−/−mice. Compared towt cells, the absence of PPARα substantially
increased the expression of TLR4, TNF-α and VEGF in these primary cells
(Fig. 5), suggesting that PPARα is required for the activation of TLR4
signaling.
We next sought to determine whether fenoﬁbrate down-regulates
TLR4 anddecreases pro-inﬂammatory cytokine production via PPARα ac-
tivation. We examined the effects of WY14643, another PPARα-speciﬁc
agonist, on TLR4 levels, NF-κB activation, and pro-inﬂammatory factorFig. 5. Deletion of PPARα increased TLR4 and inﬂammatory cytokine expressions. The
cellular levels of TNF-α, VEGF, and TLR4 in primary cultured liver cells from wt mice and
Pparα−/−mice were determined byWestern blot analysis.production in APRE 19 cells. Compared to the controls, exposure of RPE
cells to LPS signiﬁcantly increased the cellular levels of phosphorylated
NF-κB, TNF-α, and VEGF and the increases were reduced by fenoﬁbrate
or WY14643 (50 μM) to a level comparable to the controls (Fig. 6A). In
contrast, co-application of fenoﬁbrate and GW6471, a PPARα-speciﬁc
antagonist, abolished the inhibitory effects of fenoﬁbrate on the levels
of cellular phosphorylated NF-κB (Fig. 6B), TNF-α (Fig. 6C), and VEGF
(Fig. 6D), indicating that fenoﬁbrate reduced the LPS-induced production
of inﬂammatory cytokines via PPARα activation. TLR4/NF-κB signaling
was further assessed by staining RPE cells with antibodies against TLR4/
NF-κB, and the results indicated that LPS stimulation markedly increased
TLR4 signaling and induced NF-κB nuclear translocation, both of which
were completely inhibited by WY14643. Moreover, the co-application
of Wy14643 and GW6471 abolished the inhibitory effects of Wy14643
on LPS-induced TLR4/NF-κB activity (Fig. 6E). Taken together, these re-
sults suggest that PPARα activation negatively regulates the TLR4/NF-κB
pathway.
3.5. PPARα activation negatively regulated TLR4 gene
transcriptional activity
Because PPARα-mediated down-regulation of TLR4 could be caused
by transcriptional inhibition of the TLR4 gene or by an increase in TLR4
protein degradation, we examined the effects of PPARα activation on
TLR4 mRNA levels in both in vivo and in vitro models. LPS resulted in
a greater than 20-fold increase in TLR4 mRNA levels in the irises of
EIU rats, whereas feeding with fenoﬁbrate completely prevented the
increase in TLR4 expression during EIU (Fig. 7A). Consistently, LPS stim-
ulation resulted in an eight-fold increase in TLR4 expression in RPE cells,
which was fully returned to the basal level following fenoﬁbrate treat-
ment (Fig. 7B). These results suggest that the decrease in TLR4 protein
is most likely mediated through PPARα-driven down-regulation of
TLR4 gene transcription.
To conﬁrm this, we next examined the promoter transcriptional
activity of TLR4 in the presence or absence of PPARα agonists in
ARPE19 cells. As shown in Fig. 7C, compared to the controls, presence
of fenoﬁbrate or WY14643 signiﬁcantly decreased the TLR4 promoter
activity, indicating that activation of PPARα negatively regulates the
TLR4 gene transcription. Because deletion of PPARα gene resulted in
TLR4 and inﬂammatory cytokine elevation in RPE cells, we have also
assessed the impact of PPARα gene on the TLR4 gene's transcription.
As shown in Fig. 7D, down-regulation of PPARα gene expression by
transfection of a vector encoded PPARα shRNA signiﬁcantly increased
the TLR4 transcriptional activity. These results conﬁrm that PPARα
gene is a negative regulator for TLR4 transcription.
3.6. LPS antagonized PPARα activation in PPARα reporter cells
Because PPARα was shown to function as a repressor of TLR4 tran-
scription, we next evaluated whether LPS-induced TLR4 expression
was mediated through PPARα deactivation. The ability of LPS to affect
PPARα activitywas assessed using a stable transfection reporter system,
which incorporated a cDNA encoding luciferase under control of a gene
containing the ligand-binding domain of human PPARα. In this system,
the EC50 forGW590735, a PPARα agonist, to activate PPARαwas9.8 nM,
and the EC80 was 20 nM. These stable reporter cells were treated with
doses of GW590735 ranging between 0 and 20 nM in the absence or
presence of LPS ranging from 0 to 4 μg/ml for 24 h. As shown in
Fig. 8A, 4 μg/ml of LPS was able to inhibit GW590735-mediated activa-
tion of PPARα by approximately 80%. A dose–response study further
showed inhibition levels of ~25, 40, and 70% at doses of 0.5, 1, and
2 μg/ml of LPS, respectively; at doses greater than 8 μg/ml, the toxicity
of LPS prevented further measurements.
Likewise, the effects of LPS on PPARα activated by WY14643 and
fenoﬁbrate were also investigated in these stable reporter cells. As
shown in Fig. 8B, the EC50 for activation mediated by Wy14643 was
Fig. 6. PPARα agonists reduced inﬂammatory cytokine production and inhibited TLR4 signaling in a PPARα dependent manner. Conﬂuent ARPE 19 cells were cultured in amedium in the
absence or presence of 50 μM fenoﬁbrate or 50 μMWY14643 and/or with 10 μMGW6471 overnight and then exposed to 1 μg/ml LPS for 1 h. A: Representative Western blot analysis of
cellular phosphorylated NF-κB, TNF-α and VEGF levels from the same amount of whole cell lysis. B–D: Statistical analysis of phosphorylated NF-κB, TNF-α, VEGF and ICAM-1 levels after
being normalizedwithβ-actin (mean±SD,n=3, *p b 0.05, **p b 0.01). E: Representative immunocytochemistry of the activation of TLR4/NF-κB signaling. Green: TLR4; Red:NF-κB; Blue,
DAPI. Scale bar: 20 μm for large images, 50 μm for small images.
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PPARα activity by ~25, 50, and 70% at doses of 0.5, 1, and 2 μg/ml,
respectively. The EC50 for activation mediated by fenoﬁbrate was
approximately 30 μM, and the dose–response study demonstratedsimilar ﬁndings as that for WY14643 (Fig. 8C), indicating that the effect
of LPS-mediated inhibition of PPARα was speciﬁc and that LPS could
demonstrate PPARα antagonist properties. These results suggest that
LPS induced TLR level may through inhibition of PPARα.
Fig. 7. Activation of PPARα down-regulated TLR transcriptional activity. A: TLR4 mRNA levels in the eyecups from normal rats, EIU rats, and EIU rats pre-treated with fenoﬁbrate were
determined by real-time PCR and normalized by 18S RNA (mean ± SD, n= 3, **p b 0.05, ***p b 0.001). B: ARPE 19 cells at conﬂuence were exposed to normal medium; a medium con-
taining 1 μg/ml LPS in the absence or presence of fenoﬁbrate. TLR4mRNA levels from each groupwere determined by real-time PCR analysis and normalized by 18S RNA (mean± SD, n=
3, **p b 0.05, ***p b 0.001). C: Conﬂuent ARPE 19 cells were co-transfectedwith vectors containing of TLR4 promoter and PRL-TK. Twenty-four hours after achieving quiescence in a freshly
prepared medium, the cells were exposed to a culturedmedium in the presence or absence of fenoﬁbrate (50 μM) orWY14643 (50 μM) for 16 h, the same amount vehicle served as con-
trol. TLR4 transcriptional activity was determined by luciferase assay and normalized by Renilla luciferase activity (mean± SD, n=3, **p b 0.05, ***p b 0.001). D: Conﬂuent ARPE 19 cells
were transfected with plasmids of TLR4 promoter, PPARα ShRNA, and PRL-TK (to normalize the transfection efﬁciency). The transcriptional activity of TLR4 promoter was determined by
luciferase assay and normalized by Renilla luciferase activity (mean ± SD, n= 3, **p b 0.01, ***p b 0.001).
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The exact role of PPARα in regulating TLR4 signaling was unclear.
The results presented here suggest that activation of PPARα decreases
TLR4 levels and inhibits the NF-κB signaling pathway through suppres-
sion of TLR4 transcriptional activity, representing a new therapeutic
mechanism for the treatment of uveitis.
PPARα regulates and interacts with a diverse group of molecules.
PPARα activationwas reported to inhibit theNF-κB pathway and conse-
quently results in the reduction of the inﬂammatory factors COX2, IL1,
and TNF-α. But it was unclear how PPARα activation inhibits NF-κB
pathway. One explanation is that activation of PPARα inhibition of the
NF-κB pathway was through ligand-dependent trans-repression, while
another study suggested that this inhibition is through increased
expression of Iκa. However, it is still unclear whether up-regulation of
Iκa expression is associated with the TLR pathway. The data presentedin this study suggest that the ability of PPARα to down-regulate TLR4
transcription plays a central role in the regulation of its down-stream
pathway. Thus application of PPARα agonists in the treatment of TLR
related inﬂammation diseases is theoretically practicable.
Present studies of fenoﬁbrate's therapeutic effects on EAU models
(Supplemental Fig. 2A) bear out this feasibility as the presence of
MyD88 is essential for EAU induction [20,21]. In addition to providing
the evidence that activation of PPARα prevents EAU, our results also
showed that the TLR4 levels were down-regulated in EAU models
(Supplemental Fig. 2B). Interestingly, a recent study done by Okunuki
et al. showed a similar result that activation of PPARγ by pioglitazone
has a rescue effect on an EAU model by suppressing the productions
of inﬂammatory cytokines of TNF-α and IL6 [22]. Although the study
didn't mention if this inhibition was through down-regulation of TLR
transcription by PPARγ, evidences in various diseases and cells support
this possibility [23,24]. On the other hand, in addition to be a PPARγ
Fig. 8. LPS antagonized PPARα activation in PPARα reporter cells. A–C: The PPARα ligand-
activation effective concentration values of GW590735, WY14643, and fenoﬁbrate were
conﬁrmed in the reporter cells at doses of 20 nM, 40 μM, and 40 μM, respectively.
Conﬂuenced PPARα reporter cells were cultured in a medium containing 20 nM
GW590735 (A), 40 μM WY14643 (B), and 40 μM fenoﬁbrate (C), respectively, in the
presence of a range of LPS at 0–4 μg/ml overnight. The luciferase activitiesweremeasured
using a luminometer (mean ± SD, n= 4, *p b 0.05, **p b 0.01, ***p b 0.001).
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[25]. Therefore it is unclear if pioglitazone suppresses TLR4 transcription
through activation of PPAR-α, even at a lesser extent. Besides the anti-
uveitis functions, PPARα and PPARγ have the similar capability of
anti-inﬂammation in other diseases. For example, in type 1 diabetic
model, activation of PPARγ by rosiglitazone reduced the expression of
ICAM-1 and suppressed retinal leukostasis [26], a similar phenomenon
which we reported previously but with fenoﬁbrate activation of
PPARα [14]. Meanwhile, the expressions of PPARγ and PPARα are
very interesting. Both PPARγ and PPARα are abundant in human RPE
cells, where TLR4 is expressed (Supplemental Fig. 1). Therefore it is
possible that the genes regulated by PPARγ and PPARα in the RPE
cells interact and cooperate, however, the mechanism for the TLR4
down-regulation in RPE cells still requires further study.In addition to the aforementioned anti-inﬂammatory functions, the
most studied role of PPARα is regulating a number of genes involved
in free fatty acid (FFA) metabolism and insulin resistance. FFAs are
known to mediate inﬂammation and are believed to contribute to
insulin resistance. The effects of PPARα on FFAs' activity include the
up-regulated expression of genes involved in the transportation and
oxidation of FFAs, which reduce de novo FFA synthesis. Recently, several
plausible studies have revealed the ability of FFAs to stimulate TLR4-
dependent inﬂammatory pathways. For example, FFAs act as direct
ligands for TLR4, and they indirectly activate the TLR4 pathway through
binding to the adaptor protein Fetuin-A [27,28]. In addition to these
actions, FFAs have also been shown to promote the accumulation and
homodimerization of TLR4 in the cell membrane, leading to activation
of the TLR4 pathway [29]. Although our study demonstrates that
PPARα activation inhibits TLR4 transcription, it is unclear whether this
TLR4 inhibition is associated with the reduction effects of PPARα on
FFA production.
The inhibitory effect of LPS on PPARαwas previously unknown. In a
cell-based reporter assay, we found that LPS is a PPARα antagonist. The
binding of LPS to PPARα reduced PPARα activity, which contributed, at
least partially, to the effects of LPS-induced TLR4 signaling. This ﬁnding
also veriﬁed that PPARα negatively regulates the TLR4 signaling,
although the precise mechanism by which LPS inhibits the PPARα acti-
vation remains unclear. An analysis of the structure of LPS shows that
LPS mainly consists of a polysaccharide region and an endotoxin, a
speciﬁc carbohydrate lipid moiety termed lipid A, which is responsible
for the immunostimulatory activity of LPS. Crystal structure analysis of
PPARα agonists and antagonists revealed that a hydrogen bonded inter-
action between the carboxylic acid group of a PPARα agonist and Y464
on the C-terminal AF-2 helix of PPARα stabilized the receptor and the
active conﬁrmation change [30]. Normally, nuclear transcription re-
pression of gene transcription is mediated through interactions with
co-repressor proteins such as SMRT and N-CoR [31,32], which subse-
quently recruits histone deacetylases to the chromatin [33,34]. One
example is the PPARα antagonist GW6471, as a PPARα LBD bound to
GW6471 at a SMRT co-repressor motif led to SMRT motif structural
changes and prevented activation of functional conformation [30].
However, whether this mechanism applies to the interaction between
LPS and PPARα andwhether the presence of a PPARα agonist interrupts
the binding of LPS to TLR4 remain unclear, further biochemical analyses
and structure-basedmutagenesis of LPSmight provide additional infor-
mation. Overall, our current study suggests that PPARα activation has
the novel function of negatively regulating TLR4 signaling, which
could represent a new therapeutic strategy for the treatment of inﬂam-
matory diseases.
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